MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for the current fiscal year. All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |||||
| Joseph Arena | 22,405,047 | 93.09 | % | 1,663,754 | 6.91 | % | ||
| Frank Holler | 21,008,601 | 87.29 | % | 3,060,200 | 12.71 | % | ||
| Paul Lévesque | 20,966,427 | 87.11 | % | 3,102,374 | 12.89 | % | ||
| Andrew Molson | 21,067,050 | 87.53 | % | 3,001,751 | 12.47 | % | ||
| Dawn Svoronos | 20,964,213 | 87.10 | % | 3,104,588 | 2.90 | % | ||
| Elina Tea | 21,734,254 | 90.30 | % | 2,334,547 | 9.70 | % | ||
| Dale Weil | 21,009,681 | 87.29 | % | 3,059,120 | 12.71 | % | ||
| Jordan Zwick | 23,107,383 | 96.01 | % | 961,418 | 3.99 | % | ||
Frank Holler will now act as Chair of the Board of Directors of the Company.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-514-336-7800
| Last Trade: | US$1.20 |
| Daily Change: | -0.01 -0.83 |
| Daily Volume: | 4,401 |
| Market Cap: | US$55.180M |
October 10, 2024 October 09, 2024 September 09, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
